Zealand Pharma A/S (ZEAL.CO) Stock Analysis & Winston Score

Zealand Pharma is a Danish biotechnology company that discovers and develops medicines based on peptide chemistry — small protein-like molecules that can mimic or block signals in the body. Its main products target metabolic diseases like obesity and rare conditions such as short bowel syndrome. The company's lead drug, glepaglutide, and its partnership with Boehringer Ingelheim on obesity treatments have drawn significant investor attention. Zealand earns money primarily through product sales, milestone payments, and royalties from licensing deals with larger pharmaceutical partners. It is headquartered in Copenhagen, Denmark, and sells medicines mainly in the United States and Europe, with a market cap of roughly $20.8 billion reflecting strong growth expectations. The company's deep expertise in peptide science gives it a scientific edge, but its biggest risk is heavy dependence on a small number of drugs — if a key clinical trial fails or a partnership dissolves, revenue could fall sharply.